Genprex Initiates Site Recruitment for Acclaim-1 Clinical Trial for the Treatment of Non-Small Cell Lung Cancer

Source :: Business Wire. November 30, 2020
Publication Year :: 2020
Abstract: Acclaim-1 trial combines REQORSA[TM] immunogene therapy drug with AstraZeneca's Tagrisso[R] Company expects to recruit approximately 10 sites across the United States AUSTIN, Texas -- Genprex, Inc. ('Genprex' or the 'Company') [...]

Subjects :: AstraZeneca PLC -- Product development
Clinical trials
Cancer treatment
Osimertinib
Diabetes therapy -- Product development
Small cell lung cancer
Pharmaceutical industry -- Product development
Non-small cell lung cancer
Business
Business, international
Tagrisso (Medication) -- Product development

Tools